Latest News
- 
 Huntington's disease therapeutics conference 2018 – day 2DNA takes centre stage for day 2 of the Huntington's Disease Therapeutics Conference in Palm Springs 
- 
 Huntington's disease therapeutics conference 2018 – day 1Our daily roundup of the science presented at the 2018 HD Therapeutics Conference in Palm Springs 
- 
 An early role for the Huntington's disease gene – but don't believe all the headlinesA surprising new paper sheds light on the role of the HD gene early in development. Should we worry? 
- 
 New interest in an old targetPromising results in mice provide renewed optimism for mGluR5 antagonists 
- 
 Ask the expert: Q&A on the huntingtin-lowering trial programIn a Q&A coordinated by the UK HD Association, Dr Ed Wild answers questions on the recently-announced trial 
- 
 Success! ASO drug reduces levels of mutant protein in Huntington's disease patientsAmazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid 
- 
 Switch off the genome editor when you’re doneCRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD 
- 
 A new way of thinking about trials to prevent Huntington's diseaseCan we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible 
- 
 New roles for huntingtin: removing a healthy protein to understand its functionCompletely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests. 
- 
 Precision huntingtin-lowering drug trials target the mutant proteinWAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein 
